Drug Trial Radar · NCT07540832
A Study of WGI-0301 Plus Lenvatinib in Patients With Advanced HCC
Last checked: Nov 19, 2026Latest source record: Sep 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
80
Planned (sponsor's estimate)
Start
Sep 2026
Primary completion
Sep 2028
Study completion Oct 2028
Sponsor
- Lead sponsor
- Zhejiang Haichang Biotech Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Apr 20, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase II study being done at several hospitals without using a placebo. It will look at how safe and tolerable the drug WGI-0301 is when given together with Lenvatinib, how the body processes and responds to WGI-0301, and whether this combination shows early signs of working in people with advanced liver cancer.
Conditions
- Advanced Hepatocellular Carcinoma (HCC)
Interventions
WGI-0301Drug
WGI-0301 at Maximum Tolerated Dose (MTD)
WGI-0301Drug
WGI-0301 at dose level below Maximum Tolerated Dose (MTD-1)
LenvatinbDrug
Lenvatinib for patients with body weight of \<60 kg: 8 mg orally daily, for patients with body weight ≥60 kg: 12 mg orally daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Efficacy of WGI-0301 in Combination with LenvatinibTime frame: 24 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Memorial Sloan Kettering Cancer Center
New York, New York
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.